VALENTINA NASTASI: Open Payments
NPI 1003416421 · FORT SMITH, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,156 in 80 payments from 15 companies in 2025. Trend: 2023 $870 · 2024 $985 · 2025 $1,156
Food & beverage: $1,156
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $174 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 14 | $163 |
| Novartis Pharmaceuticals Corporation | 8 | $158 |
| Amgen Inc. | 22 | $143 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 6 | $83 |
| Regeneron Healthcare Solutions, Inc. | 3 | $79 |
| Kestra Medical Technology Services, Inc. | 3 | $75 |
| Merck Sharp & Dohme LLC | 5 | $72 |
| Alnylam Pharmaceuticals Inc. | 4 | $68 |
| BridgeBio Pharma, Inc. | 3 | $49 |
Products named: JARDIANCE, FARXIGA, REPATHA, LEQVIO, LifeVest, EVKEEZA, Assure WCD, VERQUVO.
Industry payments across AR — which companies pay providers there.
